Mode VC
New York

OrbiMed

OrbiMed, based in New York, backs life sciences and healthtech startups from Seed to Series B, mostly leading rounds with checks from $1 million to over $30 million.

Website LinkedIn XPortfolioPitch pageTeam page
Entry stageSeed, Series A, Series B
Check size$1M to $30M+
Leads roundsYes
FocusLife sciences, Healthtech
Latest fundApproximately $20B AUM
Investing team9 peopleNo activity since Sep

Who you would pitch at OrbiMed

9 people on the investing team, 9 of them partners who can make the call. Partners are listed first.

C. Scotland StevensGeneral PartnerHe previously worked in Global Banking & Markets at Goldman, Sachs & Co.
Carl L. GordonManaging PartnerHe leads the firm's private equity team and was a founding General Partner.
David BonitaGeneral PartnerHe previously worked as a corporate finance analyst at Morgan Stanley and UBS.
Geoffrey C. HsuGeneral PartnerHe previously worked as a financial analyst at Lehman Brothers.
Matthew RizzoGeneral PartnerHe manages the firm's royalty and credit opportunities team and has a background in pharmaceutical licensing and healthcare strategy.
Mona AshiyaGeneral PartnerShe previously worked in biotechnology equity research at J.P.
Peter ThompsonGeneral PartnerHe has experience in executive roles at Becton-Dickinson and Chiron and co-founded Trubion Pharmaceuticals.
Sven H. BorhoManaging PartnerHe previously served as a portfolio manager and senior analyst for the firm.
W. Carter NeildManaging PartnerHe previously held roles at UBS and First Chicago.

Work here and something is wrong? Ask for a correction.

Writes $1M to $30M+ checks. Its smallest check is larger than 83% of firms in the atlas.

Bars: how many firms in the atlas report each band. Highlighted: this firm.

No recent activity since September 2026. Quiet does not mean closed.

Weekly count of activity updates. Activity is not a confirmed deal.

Before you pitch

Ownership target7-10%
How to reach them[email protected]

Notable investments

InsmedEmergent BioSolutionsMyriad GeneticsCrinetics PharmaceuticalsCorvus PharmaceuticalsAdicet BioKeros Therapeutics
Founders and investors at a Mode VC gathering

Send Mode VC your deck

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.

Send your deck

Alert me when OrbiMed is active

One email when this firm shows new activity. Nothing else.

Firms like OrbiMed

New Leaf Venture Partners$1M to $30M
Easton Capital$1M to $10M
Hitachi Ventures$1M to $30M · active Oct 15
F-Prime Capital$1M to $30M+
Felicis Ventures$1M to $30M+
Alta Partners$1M to $30M

On these lists

Seed healthtech investors in New York47Series A healthtech investors in New York39Seed life sciences investors in New York26Series A life sciences investors in New York26Series B healthtech investors in New York22Series B life sciences investors in New York20Seed investors in United States2836Series A investors in United States1790

Questions

What stage does OrbiMed invest in?

OrbiMed reports entry at seed, series a, series b.

How much does OrbiMed invest?

OrbiMed reports checks of $1M to $30M+.

Does OrbiMed lead rounds?

Yes. OrbiMed says it can lead.

Who are the partners at OrbiMed?

C. Scotland Stevens (General Partner), Carl L. Gordon (Managing Partner), David Bonita (General Partner), Geoffrey C. Hsu (General Partner), Matthew Rizzo (General Partner), Mona Ashiya (General Partner).

Is OrbiMed active right now?

No recent activity since September 2026.

Work at OrbiMed? Claim or correct this profile.